Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas

被引:59
作者
Ray-Coquard, I
Ghesquière, H
Bachelot, T
Borg, C
Biron, P
Sebban, C
LeCesne, A
Chauvin, F
Blay, JY [1 ]
机构
[1] Ctr Leon Berard, F-69373 Lyon, France
[2] Inst Gustave Roussy, Paris, France
[3] Hop Edouard Herriot, Lyon, France
关键词
lymphopenia; treatment-related death; cancer; risk factors; chemotherapy; palliative;
D O I
10.1054/bjoc.2001.2011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
1-5% of cancer patients treated with cytotoxic chemotherapy die within a month after the administration of chemotherapy. Risk factors for these early deaths (ED) are not well known. The purpose of this study was to establish a risk model for ED after chemotherapy applicable to all tumour types. The model was delineated in a series of 1051 cancer patients receiving a first course of chemotherapy in the Department of Medicine of the Centre Leon Berard (CLB) in 1996 (CLB-1996 cohort), and then validated in a series of patients treated in the same department in 1997 (CLB-1997), in a prospective cohort of patients with aggressive non-Hodgkin's lymphoma (NHL) (CLB-NHL), and in a prospective cohort of patients with metastatic breast cancer (MBC series) receiving first-line chemotherapy. In the CLB-1996 series, 43 patients (4.1%) experienced early. In univariate analysis, age > 60, PS > 1, lymphocyte (ly) count less than or equal to 700 mul(-1) immediately prior to chemotherapy (d1), d1-platelet count less than or equal to 150 GL(-1), and the type of chemotherapy were significantly correlated to the risk of early death (P less than or equal to 0.01). Using logistic regression, PS > 1 (hazard ratio 3.9 (95% CI 2.0-7.5)) and d1-ly count less than or equal to 700 mul(-1) (3.1 (95% CI 1.6-5.8)) were identified as independent risk factors for ED. The calculated probability of ED was 20% (95% CI 10-31) in patients with both risk factors, 6% (95% CI 4-9) for patients with only 1 risk factor, and 1.7% (95% CI 0.9-3) for patients with none of these 2 risk factors. In the CLB-97, CLB-NHL and MBC validation series, the observed incidences of early death in patients with both risk factors were 19%, 25% and 40% respectively and did not differ significantly from those calculated in the model. In conclusion, poor performance status and lymphopenia identify a subgroup of patients at high risk for early death after chemotherapy. (C) 2001 Cancer Research Campaign.
引用
收藏
页码:816 / 822
页数:7
相关论文
共 29 条
[1]   AN INTERGROUP PHASE-III RANDOMIZED STUDY OF DOXORUBICIN AND DACARBAZINE WITH OR WITHOUT IFOSFAMIDE AND MESNA IN ADVANCED SOFT-TISSUE AND BONE SARCOMAS [J].
ANTMAN, K ;
CROWLEY, J ;
BALCERZAK, SP ;
RIVKIN, SE ;
WEISS, GR ;
ELIAS, A ;
NATALE, RB ;
COOPER, RM ;
BARLOGIE, B ;
TRUMP, DL ;
DOROSHOW, JH ;
AISNER, J ;
PUGH, RP ;
WEISS, RB ;
COOPER, BA ;
CLAMOND, GH ;
BAKER, LH .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1276-1285
[2]  
BEGAUD B, 1985, THERAPIE, V40, P115
[3]   A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy [J].
Blay, JY ;
La Cesne, A ;
Mermet, C ;
Maugard, C ;
Ravaud, A ;
Chevreau, C ;
Sebban, C ;
Guastalla, JP ;
Biron, P ;
Ray-Coquard, I .
BLOOD, 1998, 92 (02) :405-410
[4]   Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia [J].
Blay, JY ;
Chauvin, F ;
LeCesne, A ;
Anglaret, B ;
Bouhour, D ;
Lasset, C ;
Freyer, G ;
Philip, T ;
Biron, P .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :636-643
[5]  
BLAY JY, 1997, P AN M AM SOC CLIN, V16, pA56
[6]  
CHAUVIN F, 1990, B CANCER, V77, P941
[7]   COMPARISON OF A STANDARD REGIMEN (CHOP) WITH 3 INTENSIVE CHEMOTHERAPY REGIMENS FOR ADVANCED NON-HODGKINS-LYMPHOMA [J].
FISHER, RI ;
GAYNOR, ER ;
DAHLBERG, S ;
OKEN, MM ;
GROGAN, TM ;
MIZE, EM ;
GLICK, JH ;
COLTMAN, CA ;
MILLER, TP .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (14) :1002-1006
[8]   Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma:: Results of a multivariate analysis [J].
Gómez, H ;
Hidalgo, M ;
Casanova, L ;
Colomer, R ;
Pen, DLK ;
Otero, J ;
Rodríguez, W ;
Carracedo, C ;
Cortés-Funes, H ;
Vallejos, C .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2065-2069
[9]  
GRANT JP, 1981, SURG CLIN N AM, V61, P437
[10]  
HUSSAIN M, 1991, CANCER, V67, P716, DOI 10.1002/1097-0142(19910201)67:3<716::AID-CNCR2820670331>3.0.CO